Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

Todd Neale

March 29, 2020

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Conference News ACC 2018

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

Shelley Wood

March 15, 2018

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

Advertisement

What’s Going to Be Hot at ACC 2025?

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

Live From Washington: ACC 2017, Day Two

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content